Hebei Senlang Biotechnology Inc., Ltd.

This study tests a new treatment using a patient's own immune cells, modified to target and attack faulty immune cells that cause autoimmune diseases. It is for people with severe lupus or other autoimmune conditions that have not responded to standard therapies. The goal is to c…

This study tests a new treatment called S101 for people with a rare type of blood cancer (T-LBL/ALL) that has returned or not responded to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells that …

This early-phase study tests a new treatment called SENL103 for people with multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. T…